Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 205

Sort by

Sort Order Select

Journal Articles

Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia

Shanshan Suo, Dandan Zhao, Fenglin Li, Yi Zhang, Sonia Rodriguez-Rodriguez, Le Xuan Truong Nguyen, Lucy Ghoda, Nadia Carlesso, Guido Marcucci, Bin Zhang, Jie Jin

Blood (2024) 144 (12): 1343–1347.

https://doi.org/10.1182/blood.2023023400

Published: 2024

Includes: Supplemental data

Journal Articles

Identification of Characteristics and Prognostic Impact of FUS-ERG and AML1-MTG16 Fusion Genes in Adult AML Patients

Ziyue Zhou, Yile Zhou, Caihong Sun, Yiyi Yao, Liping Mao, Yi Zhang, Qing Hong, Nanfang Zhuo, Peifeng Pan, Hongyan Tong, Jie Jin, Huafeng Wang

Blood (2023) 142 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2023-185970

Published: 2023

Journal Articles

STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3 -Mutated (mut) Acute Myeloid Leukemia (AML)

Yi Zhang, Wenwen Wei, Bin Zhang, Jie Sun, Dandan Zhao, Fang Chen, Yongfang Xu, Yu Qian, Yanchun Zhao, Yutong Zhou, Wanhong Xu, Xiaoying Zhang, Long Mao, Guido Marcucci, Xiao Xu, Jie Jin

Blood (2023) 142 (Supplement 1): 5010.

https://doi.org/10.1182/blood-2023-174745

Published: 2023

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial

Shanshan Suo, Wen-Juan Yu, Ying Lu, Jiejing Qian, Liping Mao, Jin Wang, Lijing Shen, Bingzong Li, Huafeng Wang, Wenyuan MAI, Wanzhuo Xie, Xiaomin Wang, Dan Zhao, Yuanfang Liu, Chuan He, Jie Jin

Blood (2023) 142 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2023-191190

Published: 2023

Journal Articles

G Protein-Coupled Receptor 183 Plays a Prognostic Factor in Acute Myeloid Leukemia By Regulating Immune Regulation

Fenglin Li, Dong Chen, Chen Li, Haihui Zhuang, Peipei Ye, Jie Jin, Ying Lu

Blood (2023) 142 (Supplement 1): 6043.

https://doi.org/10.1182/blood-2023-185692

Published: 2023

Journal Articles

Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Blood (2023) 142 (Supplement 1): 6314.

https://doi.org/10.1182/blood-2023-189933

Published: 2023

Journal Articles

Chidamide As Maintenance in Peripheral T-Cell Lymphoma for Patients in Response after Induction Therapy: A Single Center Retrospective Study

Yanan Zhu, Juying Wei, Chunmei Yang, Wanzhuo Xie, Yanhong Tong, Wen-Juan Yu, Jie Jin

Blood (2023) 142 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2023-180495

Published: 2023

Journal Articles

The Prognostic Value of Common Cardiovascular Biomarkers in the Survival of Patients with DLBCL

Yi Xu, Yuanfei Shi, Jianai Sun, Xiaolong Zheng, Xueying Li, Jinghan Wang, Wenjuan Yu, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2023) 142 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2023-186066

Published: 2023

Journal Articles

IDH1/2-Mutated B-ALL Presents As Burkitt's Leukemia/Lymphoma-like ALL

Yu Qian, Jie Jin

Blood (2023) 142 (Supplement 1): 6063.

https://doi.org/10.1182/blood-2023-185409

Published: 2023

Journal Articles

Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Shuhua Yi, Jie Jin, Keshu Zhou, Huayuan Zhu, Kate Ma, Rili Jiang, Weige Wang, Bin Zhang, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6149.

https://doi.org/10.1182/blood-2023-182558

Published: 2023

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

Cerebrospinal Fluid IL-6 Plus IL-10 As Effective Diagnostic Biomarkers for Secondary Central Nervous System Lymphoma

Jiayan Gu, Jie Jin

Blood (2023) 142 (Supplement 1): 6160.

https://doi.org/10.1182/blood-2023-189580

Published: 2023

Journal Articles

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gaixiang Xu, Yinjun Lou, Huafeng Wang, Wen-Juan Yu, Liping Mao, Jian Huang, Chenying Li, Shanshan Suo, Hongyan Tong, Jie Jin

Blood (2023) 142 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2023-187130

Published: 2023

Journal Articles

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Nianci Chen, Jiajia Pan, Yile Zhou, Liping Mao, Yinjun Lou, Jiejing Qian, Gaixiang Xu, Juying Wei, De Zhou, Lihong Shou, Huang Li, Minchao Yan, Hui Zeng, Cuihua Fan, Gongqiang Wu, Weiying Feng, Hongyan Tong, Jie Jin, Huafeng Wang

Blood (2023) 142 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2023-182806

Published: 2023

Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2023-188444

Published: 2023

Journal Articles

Targeting HDAC9 Contributes to Degradation of MLL Fusion Oncoproteins in KMT2A-Rearranged Acute Myeloid Leukemia

Yutong Zhou, Yu Qian, Jie Jin

Blood (2023) 142 (Supplement 1): 1578.

https://doi.org/10.1182/blood-2023-185947

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Blood (2023) 142 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2023-184433

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

NARROW

Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia

Identification of Characteristics and Prognostic Impact of FUS-ERG and AML1-MTG16 Fusion Genes in Adult AML Patients

STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3 -Mutated (mut) Acute Myeloid Leukemia (AML)

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial

G Protein-Coupled Receptor 183 Plays a Prognostic Factor in Acute Myeloid Leukemia By Regulating Immune Regulation

Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Chidamide As Maintenance in Peripheral T-Cell Lymphoma for Patients in Response after Induction Therapy: A Single Center Retrospective Study

The Prognostic Value of Common Cardiovascular Biomarkers in the Survival of Patients with DLBCL

IDH1/2-Mutated B-ALL Presents As Burkitt's Leukemia/Lymphoma-like ALL

Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Cerebrospinal Fluid IL-6 Plus IL-10 As Effective Diagnostic Biomarkers for Secondary Central Nervous System Lymphoma

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Targeting HDAC9 Contributes to Degradation of MLL Fusion Oncoproteins in KMT2A-Rearranged Acute Myeloid Leukemia

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only